HR 2623
117th Congress
House
Taxation
Business expenses
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Government studies and investigations
Income tax credits
Medical research
Medical tests and diagnostic methods
Research and development
Cameron’s Law
Introduced: April 16, 2021
Introduced by:
Gottheimer, Josh
Democratic
· New Jersey
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 19, 2021
Referred to the Subcommittee on Health.
Apr 16, 2021
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 16, 2021
Introduced in House
Plain-English summary
Cameron's Law
This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit).
The bill also requires the Centers for Disease Control and Prevention to complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3
Cosponsors
1